Alzheimer’s disease is a common cause of dementia. Medicines can help manage symptoms, and disease-modifying medicines are available for some people with early Alzheimer’s. Treatment requires assessment of eligibility, expected benefit and risks. An investigational cell intervention should not be described as an established way to repair the damage or improve cognition.
The condition is progressive and shortens life expectancy, and current treatments cannot stop it. AD is generally diagnosed in older adults aged sixty-five years, but of course, it can also occur at an earlier age. Tens of millions of people worldwide live with dementia, and Alzheimer’s disease accounts for most of these cases. The number is expected to grow as populations age.[1] Alzheimer’s disease and other dementias are among the leading causes of death worldwide, and Alzheimer’s accounts for an estimated 60 to 70 percent of dementia cases. Some medical researchers have also recently begun to consider the possibility of Alzheimer’s being an autoimmune brain disease. Patients with Axial spondyloarthritis have a higher chance of getting diagnosed with Alzheimer’s dementia. Alzheimer’s disease is currently diagnosed based on several factors, including amyloid plaques and tau tangles, “neurofibrillary tangles” (NFTs), which are toxic proteins in the brain tissue and result in cognitive decline and eventually dementia. These proteins are amyloid beta (A-β) and tau. They are described as “prion-like” because misfolded forms can spread from cell to cell, although they are not infectious prions, and greater amyloid and tau buildup is linked to the progression of Alzheimer’s disease. Genetic studies have also identified many genes linked to Alzheimer’s risk, including the APOE gene, where the ApoE4 variant raises risk and the ApoE2 variant appears to lower it. For some patients, the expression was linked to genome-wide association study variants and focused on genes involved in synaptic function, lipoprotein regulation, and neuroinflammation.
What are Prions & Double-Prion Disorders?
Amyloid Plaques and Neurofibrillary Tangles – Prions are defective proteins that spread similarly to infections in the human body. These proteins force good copies of proteins into the broken, misfolded shapes that destroy the brain. The term “double-prion disorder” is sometimes used for Alzheimer’s because it involves two misfolded proteins, tau and amyloid beta. Research suggests both proteins build up in the brain and spread in a “prion-like” way: amyloid beta forms plaques between nerve cells, and tau forms tangles inside them. It can now be measured much more quickly than before. Other identified Prion Diseases include Creutzfeldt-Jakob Disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, Kuru disease, Variant Creutzfeldt-Jakob Disease (vCJD), and Fatal Familial Insomnia.
Protein structure and misfolding
Key terms used in the accompanying explanation.
- Protein folding
The three-dimensional shape of a protein.
- Misfolding
A change from the protein’s usual folded structure.
- Aggregation
The accumulation of proteins into larger groupings.
Signs & Symptoms of Alzheimer’s
Alzheimer’s shows a wide variety of symptoms, including personality changes and memory loss, followed by severely impaired intellectual/cognitive functions that arise from the disease itself or any trauma to the brain tissue. Such symptoms are NOT part of the normal aging cycle and are usually severe enough to impact the affected person’s daily activities, relationships, and independence. Conditions such as CSVD-related vascular dementia can overlap with Alzheimer’s symptoms when small-vessel damage contributes to memory, gait, or executive-function changes.
Difference between Dementia and Alzheimer’s
Patients with dementia gradually decline in memory, learning, communication, and the ability to solve simple problems. The pace varies: for many these changes develop over several years, while for others they progress more quickly, and current treatments cannot reverse the underlying damage. The rate of progression and eventual outcome of TDP-43 proteinopathy, AD, and dementia vary from patient to patient. Still, they are usually determined by the area of the brain that is affected and the type of dementia with which they are diagnosed.[2] Early diagnosis helps patients and families plan care and start treatment for symptoms. Diagnosis usually relies on a clinical assessment by a neurologist or memory specialist, cognitive testing, and brain imaging such as MRI or CT to rule out other causes, and amyloid or tau tests from PET scans, spinal fluid, or blood can add information; genetic testing is used only in selected cases. Typical symptoms & signs of Double-prion Disorders such as ALZ:
- Loss of communication skills
- Rapid Memory loss
- Motor Function, Gait and balance issues, and other symptoms of movement disorders
- Difficulty making decisions
- Difficulty with abstract thoughts
- Faulty reasoning
- Senile behavior due to cognitive impairment
- Inappropriate verbal and physical behavior
- Aphasia
- Impaired judgment
- Sundowners Syndrome
- Autonomic neuropathy
- Disorientation of time and location
- Paranoia, frequent agitation, or Hallucinations
- Complete neglect of personal hygiene and safety
People with neurodegenerative Alzheimer’s might also:
- Asks the same question repeatedly
- Cannot recognize family or friends
- Unable to remember or follow directions
- Frequent cognitive impairment, i.e., lost or disoriented in very familiar places
Sundown Syndrome
Sundowning or “late-day confusion” is a common neurological symptom of Alzheimer’s. Patients and family members caring for patients with the disease must know that confusion and frequent agitation might depend on the time of day. The most dangerous type of Sundowning behavior includes persistent Hallucinations or wandering away from home. Sundowners often experience pronounced symptoms in the late afternoon or evening. Sundowning usually occurs in middle-stage to advanced ALZ.
4 Types of Dementia
Disease symptoms are often very similar, which is why there is often trouble determining which type of dementia a patient might have. To make matters more complicated, some patients experience multiple types of overlapping symptoms and, therefore, get diagnosed with “mixed dementia.” There are also cases of familial Dementia; however, the odds are very low ( less than 5% of all cases), and genetic testing can be done to confirm or deny hereditary involvement. The four most common forms of dementia are:
- Alzheimer’s Disease is linked to a gradual buildup of amyloid beta plaques between nerve cells and tau tangles inside them over many years. The amyloid cascade hypothesis proposes that amyloid buildup starts this process.
- Lewy bodies form when an abnormal protein called alpha-synuclein accumulates in nerve cells, impairing cell signaling or function.
- Frontotemporal – occurs when the temporal or frontal lobes of the human brain shrink or are damaged.
- Vascular – usually occurs after damage to the central nervous system, such as a brain stroke.
Stem Cell Treatment for Alzheimer’s
Alzheimer’s disease distinctly affects each patient, and there are still the usual indicators that one is suffering from the disease. Early warning signs are more usually misconceived as a normal aging process or just manifestations of stress and depression. In the initial stage, the most common symptom you may notice is difficulty remembering recent events. Potential
Does stem cell therapy work for Synaptic Failure and Alzheimer’s?
Dementia symptoms and prognosis require an individual assessment. Alzheimer’s disease, vascular dementia, motor neuron disease and ataxia are different diagnoses; a symptom shared by two conditions does not show that they have the same cause or treatment. A fixed survival estimate should not be used to predict an individual’s course. The cited review discusses cell research rather than validating the fixed survival percentages or a claim that atherosclerosis causes arthritis. [3]
Neural Stem Cell Treatment for Dementia – 2026 Protocol
There are a few medications that have been researched and approved for the treatment of cognitive symptoms due to Alzheimer’s disease, including cholinesterase inhibitors (Exelon, Aricept, Razadyne) and memantine HCl (Namenda). Side effects of these medications include vomiting, loss of appetite, nausea, constipation, confusion, dizziness, headaches, and diarrhea. Alzheimer’s disease and dementia with Lewy bodies require a diagnosis-specific care plan. Lack of response to a symptomatic medicine does not establish that a cell intervention will repair brain damage. Cell-based approaches remain investigational; the proposed preparation, evidence, risks and alternatives need individual assessment.
Stem cell research and clinical trials.
A proposed cell intervention should identify its exact cell type, laboratory preparation, route and dose. Different neural cells, mesenchymal stromal cells and growth factors cannot be treated as interchangeable or assumed to replenish lost neurons. Direct delivery into the central nervous system also needs its own safety evidence and monitoring plan.
Cell sources and terminology
A guide to the source labels used in the laboratory illustration.
- Adipose tissue
ADSC
- Bone marrow
BM-MSC
- Peripheral blood
PB-MSC
- Placental tissue
P-MSC
- Umbilical cord
UC-MSC
- UC-MSC+
The Regeneration Center’s terminology used in this article.
Can stem cell transplants improve memory?
Neural precursor cells, dental-pulp-derived cells and umbilical-cord mesenchymal stromal cells are distinct preparations. Laboratory differentiation or cell survival in a research model does not establish replacement of lost human brain function, delayed Alzheimer’s progression or prevention of neuronal death. The cited Taupin review concerns adult neurogenic niches, not a trial demonstrating those patient outcomes. [4]
What role do stem cells play in Alzheimer’s disease?
Research on epigenetic regulation and adult neurogenesis helps explain cell behavior. It does not establish that a stem cell intervention is the most effective treatment for memory loss, repairs the entorhinal cortex or restores intellectual function in people with Alzheimer’s disease. [5]
Neural cells and extracellular vesicles are being investigated in neurological research. Evidence must identify the actual preparation, study population and measured outcome before a claim about cognition can be made. Findings from a model of brain injury or motor neuron disease cannot establish cognitive benefit in Alzheimer’s disease.
Stem cells for Alzheimer’s disease
Current stem cell applications for Alzheimer’s disease can include:
Cell replacement and delivery: Laboratory differentiation into a neuron-like cell does not establish integration into a patient’s brain. Claims about crossing the blood-brain barrier, replacing enzymes or clearing amyloid need product-specific evidence; changing the route of administration does not establish those benefits.
Regenerative Medicine for Alzheimer’s
Regenerative research explores cell replacement, cell signaling and tissue models. These are different strategies with different limitations. They do not establish that the center’s protocol slows or reverses Alzheimer’s disease or restores lost cognitive function. Standard neurological care and support remain necessary.
Cost of Stem Cell Therapy for Alzheimer’s Disease
The Regeneration Center treatment protocol for Alzheimer’s disease using mesenchymal stem cell transplantation with neural cells will require approximately two weeks in Bangkok. Due to varying degrees of cognitive and physical decline, our team must review each patient’s medical record before acceptance. Once our review is complete, we can offer a detailed treatment plan that includes the full treatment steps, the types and quantities of transplanted cells (which may include more than one cell type), treatment costs, and the total number of nights required for treatment.
Rehabilitation Post-Therapy – Physical rehab sessions after treatment are optional but highly recommended in Thailand or your home country. Living with ALZ disease is challenging, and depending on the patient’s timing constraints, physical rehab can be provided upon request for 2-4 hours per day and up to 6 days per week. In addition, visas and extended-stay accommodations at a hotel or furnished apartments for the patient and family can be provided upon request.
To begin the qualification process for our multi-stage regenerative medicine protocol, please prepare your recent health records and radiology scans from Brain MRIs, PET scans, or CT Scans, and contact us today.
Published Clinical Citations
[1] ^ Blurton-Jones, Mathew, Brian Spencer, Sara Michael, Nicholas A Castello, Andranik A Agazaryan, Joy L Davis, Franz-Josef Müller, Jeanne F Loring, Eliezer Masliah, and Frank M LaFerla. 2014. Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Human umbilical cord Stem cell research & therapy clinical trial, no. 2 (April 16). doi:10.1186/scrt440. https://www.ncbi.nlm.nih.gov/pubmed/25022790
[2] ^ Cook, Casey, Yong-jie Zhang, Ya-fei Xu, Dennis W Dickson, and Leonard Petrucelli. 2008. TDP-43 in neurodegenerative disorders. Expert opinion on biological therapy, no. 7. doi:10.1517/14712598.8.7.969. https://www.ncbi.nlm.nih.gov/pubmed/18549326
[3] ^Suksuphew S, Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases in Thailand. World Journal of Stem Cells. 2015;7(2):502–511. doi: 10.4252/wjsc.v7.i2.502. https://pubmed.ncbi.nlm.nih.gov/25815135/
[4] ^ Taupin P. Adult neural stem cells, neurogenic niches, and cellular therapy. Stem cell reviews. 2006;2(3):213. doi: 10.1007/s12015-006-0049-0. PubMed: 17625257.
[5] ^ Fitzsimons, Carlos P, Emma van Bodegraven, Marijn Schouten, Roy Lardenoije, Konstantinos Kompotis, Gunter Kenis, Mark van den Hurk, et al. 2014. Epigenetic regulation of adult neural stem cells: implications for Alzheimer’s disease. Molecular neurodegeneration (June 25). doi:10.1186/1750-1326-9-25. https://www.ncbi.nlm.nih.gov/pubmed/24964731